OTCMKTS:CLIGF - Clinigen Group Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$8.65
+0.30 (1.20%)

This chart shows the closing price for CLIGF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Clinigen Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLIGF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLIGF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Clinigen Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.65.

This chart shows the closing price for CLIGF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Clinigen Group. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/7/2021Royal Bank of CanadaReiterated RatingOutperform
6/10/2021Stifel NicolausDowngradeBuy ➝ Hold
11/25/2020JPMorgan Chase & Co.Initiated CoverageNeutral
7/23/2020Peel HuntDowngradeBuy ➝ Hold
3/11/2020Liberum CapitalUpgradeHold ➝ Buy
(Data available from 9/16/2016 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/18/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/18/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/17/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/16/2021

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.
Clinigen Group logo
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Read More

Today's Range

Now: $8.65
Low: $8.65
High: $8.65

50 Day Range

MA: $8.43
Low: $8.24
High: $8.65

52 Week Range

Now: $8.65
Low: $8.24
High: $11.56

Volume

N/A

Average Volume

6 shs

Market Capitalization

$1.06 billion

P/E Ratio

10.68

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Clinigen Group?

The following Wall Street sell-side analysts have issued research reports on Clinigen Group in the last twelve months: JPMorgan Chase & Co., Royal Bank of Canada, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for CLIGF.

What is the current price target for Clinigen Group?

0 Wall Street analysts have set twelve-month price targets for Clinigen Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Clinigen Group in the next year.
View the latest price targets for CLIGF.

What is the current consensus analyst rating for Clinigen Group?

Clinigen Group currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CLIGF, but not buy more shares or sell existing shares.
View the latest ratings for CLIGF.

What other companies compete with Clinigen Group?

How do I contact Clinigen Group's investor relations team?

Clinigen Group's physical mailing address is PITCAIRN HOUSE CROWN SQUARE FIRST AVENUE, Burton-on-Trent X0, DE14 2WW. The company's listed phone number is 44-12-8349-5010. The official website for Clinigen Group is www.clinigengroup.com.